Laukhtina Ekaterina, Moschini Marco, Soria Francesco, Andrea David D, Teoh Jeremy Yuen-Chun, Mori Keiichiro, Albisinni Simone, Mari Andrea, Krajewski Wojciech, Cimadamore Alessia, Abufaraj Mohammad, Enikeev Dmitry, Neuzillet Yann, Giannarini Gianluca, Xylinas Evanguelos, Kamat Ashish M, Roupret Morgan, Babjuk Marko, Witjes J Alfred, Shariat Shahrokh F, Pradere Benjamin
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy.
Eur Urol Focus. 2022 Nov;8(6):1635-1642. doi: 10.1016/j.euf.2022.03.004. Epub 2022 Mar 23.
Surveillance of the urethra and management of urethral recurrence (UR) after radical cystectomy (RC) is an area with poor evidence.
We aimed to summarize the available evidence and provide clinicians with practical recommendations on how to prevent and manage UR after RC for bladder cancer.
The MEDLINE and EMBASE databases were searched during September 2021 for studies evaluating UR after RC. The primary endpoint was oncologic outcomes for patients who experienced UR depending on different surveillance and management approaches.
Forty-three studies were included in the quantitative synthesis. According to the currently available literature, a tight-knitted surveillance protocol should be implemented for males treated with RC and nonorthotopic neobladder diversion as well as patients with prostatic involvement, tumor multifocality, bladder neck involvement, and concomitant carcinoma in situ. A survival benefit of a prophylactic urethrectomy has been reported only in patients at very high risk for UR based on clinical factors. Surveillance protocols were highly heterogeneous and poorly documented among included studies. Patients whose UR was diagnosed based on clinical symptoms had a poor prognosis. Only limited data were available on the comparative effectiveness of watchful waiting after RC versus clinical symptom screening as part of a follow-up strategy. However, the use of regular cytology and/or urethroscopy seems useful in select patients at high risk for UR. Despite limited data on the optimal management of UR, urethra-sparing approaches (transurethral resection of UR) seem to be an option for Ta (only) recurrences; a salvage urethrectomy with or without chemotherapy should be the standard for all others.
Based on the currently available literature, we have proposed an algorithm to guide the decision-making process to help identify and treat UR after RC. Given the lack of evidence on how to deal with UR and surveil patients at risk for UR, this study may invigorate research in this area of unmet need.
Early diagnosis and tailored management of urethral recurrence could help improve oncologic outcomes in these patients.
根治性膀胱切除术(RC)后尿道监测及尿道复发(UR)的处理是证据不足的领域。
我们旨在总结现有证据,并为临床医生提供关于如何预防和处理膀胱癌RC术后UR的实用建议。
2021年9月检索MEDLINE和EMBASE数据库,以查找评估RC术后UR的研究。主要终点是根据不同监测和处理方法发生UR的患者的肿瘤学结局。
43项研究纳入定量综合分析。根据现有文献,对于接受RC和非原位新膀胱改道治疗的男性以及有前列腺受累、肿瘤多灶性、膀胱颈受累和伴发原位癌的患者,应实施严密的监测方案。仅在基于临床因素有极高UR风险的患者中报道了预防性尿道切除术的生存获益。纳入研究中的监测方案高度异质性且记录不完善。根据临床症状诊断为UR的患者预后较差。关于RC术后观察等待与作为随访策略一部分的临床症状筛查的比较有效性,仅有有限的数据。然而,定期细胞学检查和/或尿道镜检查在特定UR高危患者中似乎有用。尽管关于UR最佳处理的数据有限,但保留尿道的方法(经尿道切除UR)似乎是Ta(仅)期复发的一种选择;对于其他所有情况,有或无化疗的挽救性尿道切除术应作为标准。
基于现有文献,我们提出了一种算法来指导决策过程,以帮助识别和处理RC术后的UR。鉴于缺乏关于如何处理UR以及监测UR风险患者的证据,本研究可能会推动这一未满足需求领域的研究。
尿道复发的早期诊断和针对性处理有助于改善这些患者的肿瘤学结局。